Post
PPD affects races similarly, inequities lie in mental healthcare
Postpartum depression (PPD) is depression lasting more than two weeks postpartum, and is characterised by feelings of hopelessness, anger, guilt, …
AAN 2024: Monitoring adverse events associated with gene transfer therapies
At the American Academy of Neurology (AAN) 2024 Annual Meeting, during the Neurology Year in Review Plenary Session, the safety …
How can clinical trial outsourcing and operations be optimised?
With the intention of discovering effective and budget-friendly outsourcing strategies for smooth clinical trial operations, industry leaders and keynote speakers …
Q&A: Bring your own device: How patients own tech is being used in clinical trials
Keeping track of your pulse, heart rate and oxygen saturation has never been easier, with smartwatches able to easily track …
Ocugen completes dosing in second cohort of OCU410 geographic atrophy trial
Biotechnology company Ocugen has completed dosing in the second cohort of its Phase I/II ArMaDa clinical trial of modifier gene therapy …
PPD affects races similarly, inequities lie in mental healthcare
Postpartum depression (PPD) is depression lasting more than two weeks postpartum, and is characterised by feelings of hopelessness, anger, guilt, …
AAN 2024: Monitoring adverse events associated with gene transfer therapies
At the American Academy of Neurology (AAN) 2024 Annual Meeting, during the Neurology Year in Review Plenary Session, the safety …
How can clinical trial outsourcing and operations be optimised?
With the intention of discovering effective and budget-friendly outsourcing strategies for smooth clinical trial operations, industry leaders and keynote speakers …
Q&A: Bring your own device: How patients own tech is being used in clinical trials
Keeping track of your pulse, heart rate and oxygen saturation has never been easier, with smartwatches able to easily track …
Ocugen completes dosing in second cohort of OCU410 geographic atrophy trial
Biotechnology company Ocugen has completed dosing in the second cohort of its Phase I/II ArMaDa clinical trial of modifier gene therapy …
ACTG begins trial of three immune-based therapy combinations for HIV cure
ACTG has launched A5374, a Phase I/IIa clinical trial to evaluate the safety, tolerability, and antiviral effect of a combination …
Inozyme to run Phase III trial of INZ-701 in paediatric ABCC6 deficiency
Inozyme Pharma is speaking to the US Food and Drug Administration (FDA) about running a Phase III trial of INZ-701 …
Nexsen lays out clinical plans for rapid Strep B test development
Nexsen Biotech plans to evaluate the sensitivity and specificity of its rapid point of care for Group B streptococci (GBS), …
FDA approves Phase III trial of GenFleet’s KRAS G12C inhibitor
The US Food and Drug Administration (FDA) has granted approval for GenFleet Therapeutics’ Phase III clinical trial of GFH925, a …
Kintor Pharma’s GT20029 Phase II trial meets primary endpoint
Kintor Pharma has announced that its GT20029 Phase II trial in China has met the primary endpoint, showing significant results …